Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice
- PMID: 20231782
- DOI: 10.3851/IMP1477
Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice
Abstract
Background: The pathogenesis of severe acute respiratory syndrome coronavirus (SARS-CoV) is poorly understood. Several mechanisms involving both direct effects on target cells and indirect effects via the immune system might exist. SARS-CoV has been shown in vitro to induce changes of cytokines and chemokines in various human and animal cells. We previously reported that interferon (IFN) alfacon-1 was more active against SARS-CoV infection in human bronchial epithelial Calu-3 cells than in African green monkey kidney epithelial cells on day 3 post-infection.
Methods: In the current study, we first evaluated the efficacy of IFN-alfacon 1 in Calu-3 cells during the first 7 days of virus infection. We then used the two-antibody sandwich ELISA method to detect IFN-gamma-inducible protein 10 (IP-10). We further evaluated the efficacy of antivirals directed against SARS-CoV infection in BALB/c mice.
Results: A potent, prolonged inhibition of SARS-CoV replication in Calu-3 cells with IFN-alfacon 1 was observed. Furthermore, IP-10, an IFN-inducible leukocyte chemoattractant, was detected in Calu-3 cells after SARS-CoV infection. Interestingly, IP-10 expression was shown to be significantly increased when SARS-CoV-infected Calu-3 cells were treated with IFN alfacon-1. IP-10 expression was detected in the lungs of SARS-CoV-infected BALB/c mice. Significantly high levels of mouse IP-10 in BALB/c mice was also detected when SARS-CoV-infected mice were treated with the interferon inducer, polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine and carboxymethyl cellulose (poly IC:LC). Treatment with poly IC:LC by intranasal route were effective in protecting mice against a lethal infection with mouse-adapted SARS-CoV and reduced the viral lung titres.
Conclusions: Our data might provide an important insight into the mechanism of pathogenesis of SARS-CoV and these properties might be therapeutically advantageous.
Similar articles
-
Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model.Antiviral Res. 2017 Mar;139:1-12. doi: 10.1016/j.antiviral.2016.12.007. Epub 2016 Dec 9. Antiviral Res. 2017. PMID: 27956136 Free PMC article.
-
Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.Biochem Biophys Res Commun. 2008 Jun 20;371(1):110-3. doi: 10.1016/j.bbrc.2008.04.006. Epub 2008 Apr 10. Biochem Biophys Res Commun. 2008. PMID: 18406349 Free PMC article.
-
SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium.Virus Res. 2008 Apr;133(1):33-44. doi: 10.1016/j.virusres.2007.03.013. Epub 2007 Apr 23. Virus Res. 2008. PMID: 17451829 Free PMC article. Review.
-
Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.Antivir Chem Chemother. 2006;17(5):275-84. doi: 10.1177/095632020601700505. Antivir Chem Chemother. 2006. PMID: 17176632
-
Pathogenesis of severe acute respiratory syndrome.Curr Opin Immunol. 2005 Aug;17(4):404-10. doi: 10.1016/j.coi.2005.05.009. Curr Opin Immunol. 2005. PMID: 15950449 Free PMC article. Review.
Cited by
-
Forms and Methods for Interferon's Encapsulation.Pharmaceutics. 2021 Sep 22;13(10):1533. doi: 10.3390/pharmaceutics13101533. Pharmaceutics. 2021. PMID: 34683824 Free PMC article. Review.
-
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.Sci Rep. 2013;3:1686. doi: 10.1038/srep01686. Sci Rep. 2013. PMID: 23594967 Free PMC article.
-
Chemokine Regulation During Epidemic Coronavirus Infection.Front Pharmacol. 2021 Feb 4;11:600369. doi: 10.3389/fphar.2020.600369. eCollection 2020. Front Pharmacol. 2021. PMID: 33613280 Free PMC article. Review.
-
Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.Future Virol. 2011 May;6(5):615-631. doi: 10.2217/fvl.11.33. Future Virol. 2011. PMID: 21765859 Free PMC article.
-
Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model.Antiviral Res. 2017 Mar;139:1-12. doi: 10.1016/j.antiviral.2016.12.007. Epub 2016 Dec 9. Antiviral Res. 2017. PMID: 27956136 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous